I also take T3 & Levo and feel so well it works for me BUT at the moment I am very concerned about the following:-
PRESCQIPP AND BULLETIN 121 - LIOTHYRONINE.
You may, or may not be aware that an organisation calling themselves PrescQIPP' are working with local CCG's and the NHS in an attempt to try to save them money. This would be a good thing, but the problem is the WAY they believe they can save the NHS £20 million. This is by removing T3 (liothyronine) from the NHS prescription list. Their Bulletin 121 in which they give details of this makes it sound as if they have the best interest of everybody at heart, especially the patient, but how can this be.
I have written a rebuttal to PrescQIPP on behalf of TPA, as I found they had not cited one single reference to research or evidence that would back up any of their statements. You can find the PrescQIPP's Bulletin 121 and the TPA rebuttal (which is long of necessity) on the Home Page of our website. I have no idea how PrescQIPP will respond, but what they have taken on has huge implications and members who are being prescribed T3 at the moment should know about these.
Also, we are getting many reports from members who's GP is telling them they are no longer allowed to prescribe T3 for them. Some claim that a circular has apparently been sent to ~GP's in their area from CCG,s but I have not seen a copy of such a circular. If your GP has told you that he is no longer allowed to continue its prescription, please will you let me know simply giving me the name of your local CCGT. Your name will not be mentioned. We are trying to compile a list of such CCG as this is important.
HUGE PRICE HIKE OF LIOTHYRONINE BY AMDIPHARM MERCURY (AMCo)
Liothyronine (L-T3) is a long-established, safe and effective thyroid hormone replacement for those who continue suffering symptoms whilst on L-T4-monotherapy. Liothyronine is of simple construction, and is cheap to both develop and manufacture.
Branded medicines are subject to price regulation. Up until 2007, the price of the brand Tertroxin therefore remained stable at £15.92 for 100 tablets. However, it does appear that the brand name Tertroxin may have been removed by the present owner Amdipharm Mercury Ltd., (AMCo) in order to by-pass price regulation. The product is now marketed as generic liothyronine. In March 2016, the cost of liothyronine had risen to a staggering £922.44 for 100 tablets (based on 28 tablets at £256.20).
Generic drugs are, in theory, subject to competition. The UK liothyronine is therefore no longer subject to price regulation. Amdipharm Mercury Ltd.( AMCo) have written to TPA stating that their UK liothyronine formula is “unique and not interchangeable with other products in the market”. However, there is NO competition. The Department of Health appear to have handed the monopoly of manufacturing and selling liothyronine in the UK to Amdipharm Mercury Ltd. (AMCo). Resultantly, there is thus NO competition. Incidentally, President Obama became involved in a similar case in the United States. 
Doctors can no longer write the brand name Tertroxin on a prescription form. They have to write instead liothyronine’. As a result, the NHS local CCG’s are writing to doctors advising that they should no longer prescribe generic T3, because of the huge cost to the NHS, and are recommending that they prescribe levothyroxine as an alternative. The consequences of this can be devastating to those approximately quarter of a million patients in the UK who need T3, as can be ascertained from the evidence given above.
Given the seriousness of the matter, and also considering PrescQIPP’s ‘OBJECTS’, an investigation into the reasons for why the cost to the NHS has been allowed to continue rising, should be the first priority. Investigation into this matter should also delve into why there was no action taken by the Department of Health, and/or the MHRA, despite them having been approached by numerous MP’s asking for an explanation. The potential for devastating effects on patient’s lives should also be recognised, and a case for medical negligence should be given consideration.
It is of great concern that AMCo have countered that their ‘generic’ UK liothyronine is “ in fact “unique and not interchangeable with other products in the market”. The MHRA, and British Generics, inform us that generics that are NOT interchangeable MUST HAVE A BRAND NAME. A previously mentioned, the brand Tertroxin was removed some time in 2007, resulting in the product being marketed as generic liothyronine instead.
"A generic medicine contains the same active ingredient as the equivalent original branded drug, and is marketed once the originator's patent protection has expired. Generics are authorised to the same standards of safety, quality and efficacy as original branded drugs, and have to demonstrate in clinical studies that they are bioequivalent to the original product: i.e., they deliver equal medical benefits to the patient.
Generic medicines are therefore normally interchangeable with the equivalent branded drug. On the rare occasions where this is not the case, the MHRA (Medicines and Healthcare products Regulatory Agency) requires generic medicines to have a brand name so that patients may be maintained on a single manufacturer's product."
It is of great concern that in Europe, the cost of L-T3 is a mere fraction of what it costs in the UK.
Sweden - 100 tablets of L-T3 = £21.10
Finland - 100 tablets of L-T3 = £15.81
Norway -100 tablets of L-T3 20mcgs – NOK 254.50 = 27.51€ = £21.65
Denmark -100 tablets of L-T3 20mcgs – Thybon 20 Henning = DKK 190 = 25.53€ = £20.09
Germany - 100 tablets of L-T3 20mcgs -30.15€
Turkey -100 tablets of L-T3 – Tiromel = £1.25 (info. from private correspondence)
UK - 100 tablets of T3 - Liothyronine = £922.44 (based on 28 tablets at £256.20)
THE TIMES HA VE GOT THE STORY - 3 JUNE 2006'
'EXTORTIONATE' PRICES ADD £260M TO NHS DRUG BILL.
There was a massive story in The Times Newspaper yesterday and, I am told, in The Times today too. There is a full feature article covering the whole of page 1, more on Page two, and on Page 6 and 7 is a double page spread, featuring, in particular four pharmaceutical companies that are involved. Of course, Amdapharm Mercury (features strongly).
THIS IS SO WRONG!